Andere Sprachen Guardant Health, Inc.

Aktien

A2N5RY

US40131M1099

GH

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 26.04.2024			% 5 Tage	% 1. Jan.
17,35 ^USD	+1,11 %		+7,97 %	-35,86 %

15.04.	GUARDANT HEALTH, INC. : Goldman Sachs behält seine Kaufempfehlung bei	ZM
03.04.	Guardant Health präsentiert Daten zur Anwendung der Epigenomik für die Präzisionsonkologie auf der AACR-Jahrestagung 2024	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

FDA Advisory Panel Review of Guardant Health's Shield Blood Test to Screen for Colorectal Cancer to Be Held on May 23	23.04.
Sector Update: Health Care Stocks Increase Late Afternoon	22.04.
Sector Update: Health Care Stocks Rise in Monday Afternoon Trading	22.04.
Guardant Health Says FDA Advisory Panel Will Review Shield Blood Test for Colorectal Cancer Screening; Shares Rise	22.04.
FDA Advisory Panel Review of Guardant Health’s Shield™ Blood Test to Screen for Colorectal Cancer to Be Held on May 23	22.04.
Guardant Health to Report First Quarter 2024 Financial Results on May 9, 2024	18.04.
Guardant Health to Present Data Highlighting Application of Epigenomics to Advance Precision Oncology at 2024 AACR Annual Meeting	03.04.
Guardant Health to Present Data Highlighting Application of Epigenomics to Advance Precision Oncology at 2024 AACR Annual Meeting	03.04.
Guardant Health - Royal Marsden And Guardant Health Partnership Provides State-of-the-art Blood Test To Benefit Lung Cancer Patients In Expanded NHS Study	25.03.
50 valores para invertir en IA, salud, movilidad y energía	25.03.
50 aandelen om te beleggen in KI, gezondheid, mobiliteit en energie	23.03.
50 titoli per investire in AI, salute, mobilità ed energia	22.03.
50 valeurs pour investir dans l'IA, la Santé, la Mobilité et l'Energie	22.03.
Blood test shows 83% accuracy for detecting colorectal cancer in trial	13.03.
Guardant Health ECLIPSE Study Data Demonstrating Efficacy of Shield Blood-based Test for Colorectal Cancer Screening to be Published in The New England Journal of Medicine	13.03.
Guardant Health, Inc. Announces Results from the ECLIPSE Study Showing the Effectiveness of Its Shield Blood Test for Detecting Colorectal Cancer	13.03.
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	06.03.
Guardant Health, Inc. - New Survey, Patients and Physicians Overwhelmingly Agree Blood Tests Could Help Close the Colorectal Cancer Screening Gap	04.03.
New Survey: Patients and Physicians Overwhelmingly Agree Blood Tests Could Help Close the Colorectal Cancer Screening Gap	01.03.
Guardant Health Q4 Adjusted Loss Narrows as Revenue Rises	23.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Guardant Health, Inc.

Aktien

A2N5RY

US40131M1099

GH

Andere Sprachen

Filter